McKesson is now a nonexclusive distributor of Qiagen's QIAstat-Dx syndromic system for respiratory and gastrointestinal diseases in smaller U.S. hospitals, and it is also managing sales in nonacute retail pharmacies.
The QIAstat-Dx respiratory panel for detecting more than 20 respiratory viral and bacterial pathogens was cleared by the U.S. Food and Drug Administration (FDA) in May for use with the QIAstat-Dx syndromic testing system.
McKesson and Qiagen are targeting smaller facilities. There are approximately 2,000 hospitals in the U.S. with 200 or fewer beds, accounting for about 10% of the total market for syndromic testing nationally and $650 million in annual sales, according to the companies.
